STAT3 and esophageal squamous cell carcinoma: These results indicated that Notch signaling inhibitors enhanced the anticancer effect of chemotherapeutic agents in treating ESCC with activated Notch signaling, suggesting that the NOTCH1–USP5–STAT3 axis may be a promising therapeutic target.